eCourse
Patent Eligibility: Section 101 Challenges and the New USPTO Guidelines
Contains material from Mar 2016
Patent Eligibility: Section 101 Challenges and the New USPTO Guidelines
3.91 out of 5 stars
What was the overall quality of the course (presentation, materials, and technical delivery)?
Rate the overall teaching effectiveness and presentation skills of faculty for the course.
How would you rate the value of the materials provided as part of the course?
Somewhat difficult to follow which slide the speakers were on. It would be nice to have an automatic linking between the audio and the slides.
Technical Questions?
512.475.6700
service@utcle.org
Session 1: Patent Eligible Claims Post-Alice: Section 101 and the New USPTO Guidelines - You’ve read Alice and understand when a claim recites an abstract idea and when a claim recites “something more,” right? Wrong! With the new USPTO guidelines providing insight into the meaning of these concepts, and examiners now asking applicants to reference those guidelines in identifying the claims in their application, hear discussion of these concepts and the impact on patent applications.
Session 2: Sequenom and Section 101 Challenges in Diagnostics and Personalized Medicine - Explore the significant challenges facing diagnostics and personalized medicine in the wake of Mayo, Myriad and Alice, as illustrated by the Federal Circuit decision in Sequenom, the implications for industry and public health, and possible strategies for overcoming difficult recent jurisprudence.
Session 2: Sequenom and Section 101 Challenges in Diagnostics and Personalized Medicine - Explore the significant challenges facing diagnostics and personalized medicine in the wake of Mayo, Myriad and Alice, as illustrated by the Federal Circuit decision in Sequenom, the implications for industry and public health, and possible strategies for overcoming difficult recent jurisprudence.
Includes: Audio Paper Slides
Preview mode.
You must be signed in, have purchased this eCourse,
and the eCourse must be active
to have full access.
Preview Sessions
Show session details
1.
Patent Eligible Claims Post-Alice: Section 101 and the New USPTO Guidelines (Mar 2016)
Dale S. Lazar, Robert Bahr
0.75
0.00
0.00
Preview Materials
Download session materials for offline use
Session 1
—51 mins
Patent Eligible Claims Post-Alice: Section 101 and the New USPTO Guidelines (Mar 2016)
You’ve read Alice and understand when a claim recites an abstract idea and when a claim recites “something more,” right? Wrong! With the new USPTO guidelines providing insight into the meaning of these concepts, and examiners now asking applicants to reference those guidelines in identifying the claims in their application, hear discussion of these concepts and the impact on patent applications.
Originally presented: Mar 2016 Advanced Patent Law Institute
Dale S. Lazar,
DLA Piper LLP US - Reston, VA
Robert Bahr,
Acting Deputy Commissioner for Patent Examination Policy, U.S. Patent and Trademark Office - Alexandria, VA
Show session details
2.
Sequenom and Section 101 Challenges in Diagnostics and Personalized Medicine (Mar 2016)
Courtenay C. Brinckerhoff, Hans Sauer, Adam Mossoff
0.75
0.00
0.00
Preview Materials
Download session materials for offline use
Slides
(pdf)
5 pgs
Slides
(pdf)
7 pgs
Session 2
—50 mins
Sequenom and Section 101 Challenges in Diagnostics and Personalized Medicine (Mar 2016)
Explore the significant challenges facing diagnostics and personalized medicine in the wake of Mayo, Myriad and Alice, as illustrated by the Federal Circuit decision in Sequenom, the implications for industry and public health, and possible strategies for overcoming difficult recent jurisprudence.
Originally presented: Mar 2016 Advanced Patent Law Institute
Courtenay C. Brinckerhoff,
Foley & Lardner LLP - Washington, DC
Hans Sauer,
Biotechnology Innovation Organization - Washington, DC
Adam Mossoff,
George Mason University School of Law - Arlington, VA